Proteomics in early detection of cancer.
Early detection is critical in cancer control and prevention. Biomarkers help in this process by providing valuable information about a the status of a cell at any given point in time. As a cell transforms from nondiseased to neoplastic, distinct changes occur that could be potentially detected through the identification of the appropriate biomarkers. Biomarker research has benefited from advances in technology such as proteomics. We discuss here ongoing research in this field, focusing on proteomic technologies. The advances in two-dimensional electrophoresis and mass spectrometry are discussed in light of their contribution to biomarker research. Chip-based techniques, such as surface-enhanced laser desorption, and ionization and emerging methods, such as tissue and antibody arrays, are also discussed. The development of bioinformatic tools that have and are being developed in parallel to proteomics is also addressed. This report brings into focus the efforts of the Early Detection Research Network at the National Cancer Institute in harnessing scientific expertise from leading institutions to identify and validate biomarkers for early detection and risk assessment.
Srinivas
P R
PR
Division of Cancer Prevention, National Cancer Institute, Rockville, MD 20852, USA.
Srivastava
S
S
Hanash
S
S
Wright
G L
GL
D000906:Antibodies; D019295:Computational Biology / Q000379:methods; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D020543:Proteome; D012106:Research; D014481:United States
D000906:Antibodies; D020543:Proteome